L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y.
Marrocco I, et al. Among authors: rudnitsky a.
Cell Rep Med. 2023 Aug 15;4(8):101142. doi: 10.1016/j.xcrm.2023.101142. Epub 2023 Aug 8.
Cell Rep Med. 2023.
PMID: 37557179
Free PMC article.